Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M964Revenue (TTM) $M125Net Margin (%)--Altman Z-Score--
Enterprise Value $M--EPS (TTM) $-0.1Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M21.0ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with HPTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HPTXMario Gabelli 2015-06-30 Sold Out -0.04%$45.79 - $46.14
($45.95)
$ 45.990%Sold Out0
HPTXMario Gabelli 2015-03-31 Buy 0.04%$23.34 - $45.98
($29.92)
$ 45.9954%New holding169,000
HPTXJoel Greenblatt 2015-03-31 Sold Out -0.0024%$23.34 - $45.98
($29.92)
$ 45.9954%Sold Out0
HPTXJoel Greenblatt 2014-12-31 Reduce$20.4 - $25.23
($22.43)
$ 45.99105%Reduce -30.66%12,557
HPTXJoel Greenblatt 2014-09-30 Buy $21.96 - $27.64
($24.83)
$ 45.9985%New holding18,109
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HPTX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


HPTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Nash Christine ASVP & Chief Commercial Officer 2015-03-17Sell10,000$37.5622.44view
Nash Christine ASVP & Chief Commercial Officer 2015-03-10Sell9,900$29.6355.21view
Nash Christine ASVP & Chief Commercial Officer 2015-03-10Sell10,000$35.0831.1view
Scharschmidt Bruce FrederickSVP & Chief Medical Officer 2015-02-27Sell29,800$29.8953.86view
Nash Christine ASVP & Chief Commercial Officer 2015-01-20Sell5,000$24.8285.29view
Scharschmidt Bruce FrederickSVP & Chief Medical Officer 2014-07-02Sell200$2864.25view
KOLLURI KRISHNA KITTU10% Owner 2014-06-06Sell120$27.1969.14view
BARRIS PETER J10% Owner 2014-06-06Sell1,134$26.970.97view
BASKETT FOREST10% Owner 2014-06-06Sell1,377$26.970.97view
BARRETT M JAMES10% Owner 2014-06-06Sell1,430$26.8871.09view

Quarterly/Annual Reports about HPTX:

    News about HPTX:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    5 Key Drugs That Just Won EU Endorsements Sep 25 2015
    Great Point Partners Trims Its Stake In Alcobra Ltd (ADHD) Apr 22 2015
    The Bull Case: Supply & Demand Edition Mar 31 2015
    The Bull Case: Supply & Demand Edition Mar 31 2015
    Biz Break: Brisbane biotech bought for $1.1 billion as boom barrels on Mar 30 2015
    Horizon Pharma buying Hyperion for about $1.1 billion Mar 30 2015
    GLOBAL MARKETS-Stocks rally on merger activity; dollar gains Mar 30 2015
    Wall St. rebounds from recent losses; deals help Mar 30 2015
    Norcraft and Auspex are big market movers Mar 30 2015
    US STOCKS-Wall St bounces back from recent losses; deals help Mar 30 2015
    Horizon Pharma buying Hyperion for about $1.1 billion Mar 30 2015
    US STOCKS-Wall St higher as biotechs rally on M&A deals Mar 30 2015
    US STOCKS-Futures point to higher open on M&A activity Mar 30 2015
    Ireland's Horizon to buy U.S. drugmaker Hyperion for $1.1 bln Mar 30 2015
    Connecture Inc (CNXR), Hyperion Therapeutics Inc (HPTX): Top 5 Healthcare Picks of Great Point... Mar 02 2015
    Hyperion tops Street 4Q forecasts Feb 26 2015
    Hyperion tops 3Q revenue forecasts Nov 06 2014
    Hyperion, Clal Biotech resolve dispute over diabetes drug Oct 07 2014
    Hyperion reports diabetes drug misconduct Sep 08 2014
    Evotec profit target in danger after drug trial halted Sep 08 2014

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)